Education
About Us
Working with TipRanks
Follow Us
Mirum Pharmaceuticals Inc (MIRM)
NASDAQ:MIRM
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.32Last Year’s EPS
-0.52Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: 9.85%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth, strong performance of key products, and multiple regulatory approvals, indicating positive business momentum. However, high operating expenses and non-cash charges were noted as challenges.Company Guidance
In the recent call, Mirum Pharmaceuticals provided updated guidance for the fiscal year 2025 following a record-breaking first quarter. The company reported total revenues of $111.6 million, representing a 61% growth over the same period last year. As a result of robust growth from their commercial medicines, Mirum raised its full-year revenue guidance to between $435 million and $450 million. Key drivers included strong sales of LIVMARLI, which saw global net product sales reach $73.2 million, a growth of over 70% compared to the first quarter of 2024. U.S. sales of LIVMARLI were $49.5 million, highlighting strong new patient demand. Additionally, Mirum achieved three regulatory approvals since the beginning of the year, further bolstering its growth prospects. The company also reported that it was cash flow positive for the quarter, with a cash, cash equivalents, and investments balance of $298.6 million as of March 31st, 2025.Record-Breaking Revenue Growth
Mirum Pharmaceuticals reported total revenues of $111.6 million for Q1 2025, representing a 61% growth over the first quarter of the previous year.
Updated Revenue Guidance
The company increased its full-year revenue guidance to $435 million to $450 million, driven by robust growth across its commercial medicines.
Regulatory Approvals
Three important regulatory approvals were received, including FDA approval of CTEXLI for CTX treatment and LIVMARLI's approval in Japan for PFIC and Alagille syndrome.
Strong Performance of LIVMARLI
Total global net product sales for LIVMARLI grew to $73.2 million in Q1, an increase of over 70% compared to Q1 2024.
Pipeline Progress
The VISTAS study of Volixibat in PSC is nearing enrollment completion, with top-line data expected in Q2 2026. The VANTAGE study in PBC showed a 3.8 point reduction from baseline in pruritus.
Improved Financial Position
Operating cash flow was positive for the quarter, with a cash contribution margin improvement from approximately 47% to 53% year-over-year.
---
MIRM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MIRM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $41.22 | $45.24 | +9.75% |
Feb 26, 2025 | $50.52 | $46.98 | -7.01% |
Nov 12, 2024 | $41.61 | $42.28 | +1.61% |
Aug 07, 2024 | $38.96 | $39.87 | +2.34% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Mirum Pharmaceuticals Inc (MIRM) report earnings?
Mirum Pharmaceuticals Inc (MIRM) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Mirum Pharmaceuticals Inc (MIRM) earnings time?
Mirum Pharmaceuticals Inc (MIRM) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MIRM EPS forecast?
MIRM EPS forecast for the fiscal quarter 2025 (Q2) is -0.32.
---